COMPOSITIONS ET UTILISATION D'UN MOTIF DE LIAISON AU FIBRINOGENE EN PRESENCE D'EFB ET DE COA, POUR VACCIN CONTRE LE STAPHYLOCOCCUS AUREUS ET ADMINISTRATION DE MEDICAMENT
THE TEXAS A&M UNIVERSITY SYSTEM;UNIVERSITY MEDICAL CENTER UTRECHT, THE NETHERLANDS
发明人:
KO, YA-PING,HOOK, MAGNUS,ROOIJAKKERS, SUZAN HM,BROWNING, MARY BETH
申请号：
CA2952930
公开号：
CA2952930A1
申请日:
2014.10.15
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N- terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
